HC Wainwright Comments on Transcat, Inc.’s FY2025 Earnings (NASDAQ:TRNS)

Transcat, Inc. (NASDAQ:TRNS) – Research analysts at HC Wainwright dropped their FY2025 earnings per share estimates for shares of Transcat in a report issued on Tuesday, April 16th. HC Wainwright analyst S. Buck now forecasts that the scientific and technical instruments company will earn $2.31 per share for the year, down from their previous estimate of $2.41. HC Wainwright currently has a “Buy” rating and a $124.00 target price on the stock. The consensus estimate for Transcat’s current full-year earnings is $1.33 per share.

A number of other equities analysts have also issued reports on the company. Oppenheimer restated an “outperform” rating and issued a $125.00 target price (up previously from $120.00) on shares of Transcat in a research note on Thursday. TheStreet upgraded Transcat from a “c+” rating to a “b” rating in a research note on Wednesday, January 31st.

Transcat Stock Performance

Shares of TRNS opened at $108.04 on Thursday. Transcat has a 12 month low of $74.89 and a 12 month high of $115.41. The stock has a fifty day moving average price of $108.50 and a 200-day moving average price of $102.00. The company has a current ratio of 3.37, a quick ratio of 2.81 and a debt-to-equity ratio of 0.01. The firm has a market cap of $953.89 million, a PE ratio of 83.11 and a beta of 0.59.

Transcat (NASDAQ:TRNS) last issued its quarterly earnings data on Monday, January 29th. The scientific and technical instruments company reported $0.38 EPS for the quarter, beating the consensus estimate of $0.35 by $0.03. Transcat had a return on equity of 9.32% and a net margin of 4.16%. The firm had revenue of $65.17 million during the quarter, compared to analyst estimates of $63.36 million.

Insider Buying and Selling

In related news, CEO Lee D. Rudow sold 5,000 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $111.30, for a total value of $556,500.00. Following the completion of the transaction, the chief executive officer now owns 108,478 shares in the company, valued at approximately $12,073,601.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Transcat news, CEO Lee D. Rudow sold 5,000 shares of Transcat stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $111.30, for a total transaction of $556,500.00. Following the completion of the transaction, the chief executive officer now owns 108,478 shares in the company, valued at approximately $12,073,601.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Lee D. Rudow sold 2,373 shares of Transcat stock in a transaction dated Saturday, March 30th. The shares were sold at an average price of $111.43, for a total value of $264,423.39. Following the transaction, the chief executive officer now owns 103,688 shares of the company’s stock, valued at approximately $11,553,953.84. The disclosure for this sale can be found here. Insiders sold 8,073 shares of company stock worth $900,023 in the last 90 days. Insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Transcat

Institutional investors have recently modified their holdings of the stock. US Bancorp DE raised its stake in shares of Transcat by 137.9% during the 1st quarter. US Bancorp DE now owns 345 shares of the scientific and technical instruments company’s stock valued at $28,000 after buying an additional 200 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Transcat by 345.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,234 shares of the scientific and technical instruments company’s stock valued at $135,000 after buying an additional 957 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in shares of Transcat by 162.3% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,626 shares of the scientific and technical instruments company’s stock valued at $92,000 after acquiring an additional 1,006 shares during the period. Barclays PLC grew its position in shares of Transcat by 533.1% during the 4th quarter. Barclays PLC now owns 1,912 shares of the scientific and technical instruments company’s stock valued at $135,000 after acquiring an additional 1,610 shares during the period. Finally, Price T Rowe Associates Inc. MD acquired a new stake in shares of Transcat during the 4th quarter valued at about $226,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.